During a year in which legislative activity was restrained by a variety of factors, most notably the Senate’s inability to maintain a consistent majority, the New York State Legislature nonetheless still passed 641 bills,...more
6/27/2018
/ Biologics ,
Controlled Substances ,
Cosmetics ,
Decriminalization of Marijuana ,
Legislative Agendas ,
Manufacturers ,
Medical Devices ,
Medical Marijuana ,
Pain Management ,
Personal Care Products ,
Pesticides ,
Pharmaceutical Industry ,
Prescription Drugs ,
Proposed Legislation ,
Reclassification Rules ,
Regulatory Oversight ,
Regulatory Requirements ,
Risk Assessment ,
Risk Mitigation ,
State and Local Government
Several provisions in the recently adopted 2018-19 New York State Budget (the “Enacted Budget”) are intended to address the ongoing opioid crisis. As discussed in a prior post, some were focused on pharmaceutical...more
4/9/2018
/ Drug & Alcohol Abuse ,
Drug Treatment ,
Healthcare Facilities ,
Mental Health ,
Opioid ,
Outpatient Services ,
Pain Management ,
Prescription Drugs ,
Regulatory Oversight ,
State and Local Government ,
State Budgets ,
State Funding ,
Substance Abuse
Notwithstanding the enactment of a first-in-the-nation drug spending cap last year, in light of the $4.4 billion deficit and ongoing concerns about the opioid crisis it was inevitable that this year New York State would once...more
4/5/2018
/ Drug Distribution ,
Drug Pricing ,
Generic Drugs ,
Opioid ,
Pain Management ,
Pharmaceutical Industry ,
Pharmacies ,
Prescription Drugs ,
Rebates ,
Regulatory Oversight ,
State and Local Government ,
State Budgets ,
State Medicaid Programs